Search our Database of Scientific Publications and Authors

I’m looking for a

    3376 results match your criteria Plaque Psoriasis

    1 OF 68

    The management of moderate-to-severe chronic plaque psoriasis.
    G Ital Dermatol Venereol 2017 May 23. Epub 2017 May 23.
    Dermatology Department, University of Pisa, Pisa, Italy -
    Recent approval and marketization of novel treatments have widened the range of therapeutic opportunities for moderate-to-severe psoriasis. In the next years, this panorama will be further enlarged as many other agents, both oral small molecules and biologics, have passed phase III and are expected to be approved, and subsequently marketed, shortly. In spite of this array of therapeutic possibilities, there is still an unmet need for an appropriate treatment in a large number of cases. Read More

    Expression of Angiogenic Factors in Psoriasis Vulgaris.
    J Clin Diagn Res 2017 Mar 1;11(3):EC23-EC27. Epub 2017 Mar 1.
    Resident, Department of Pathology, Coimbatore Medical College and Hospital, Coimbatore, Tamil Nadu, India.
    Introduction: Psoriasis is a chronic inflammatory skin disease characterized by epidermal hyperproliferation, abnormal differentiation and inflammatory infiltration in the dermis. The dermal microvascular expansion associated with abnormal orientation and dilatation of capillaries in the biopsies of the psoriatic skin suggest that the disease is dependent on angiogenesis.

    Aim: To analyze and compare the immunohistochemical expression of angiogenic factors - Vascular Endothelial Growth Factor (VEGF), von Willebrand Factor (vWF) and CD 34 in skin biopsies of psoriasis cases with control skin samples; and to correlate the expression of angiogenic factors with Psoriasis Area and Severity Clinical Index (PASI SCORE). Read More

    Paraoxonases and psoriasis: negative imbalance of anti--oxidant endogenous mechanisms.
    G Ital Dermatol Venereol 2017 May 16. Epub 2017 May 16.
    Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy -
    Backgroung: Numerous reports have shown that psoriasis patients are more exposed to lipoprotein peroxidation and to a decrease in the activity of paraoxonase (PON)1, an anti-oxidant and anti-inflammatory enzyme. Thus, it has been suggested that malfunction of the anti-oxidant system and an increased production of reactive oxygen species drive immune inflammatory events, that result in progressive skin cell damage in patients with psoriasis. The PON protein family, including PON1, PON2 and PON3, is one of the most important endogenous defense mechanisms against oxidative stress. Read More

    No evidence for induction of autoantibodies or autoimmunity during treatment of psoriasis with ustekinumab.
    Br J Dermatol 2017 May 16. Epub 2017 May 16.
    Department of Dermatology, Instituto de Investigación Sanitaria Princesa (IIS-IP), Hospital Universitario la Princesa, Madrid, Spain.
    Ustekinumab is a human monoclonal antibody directed against the p40 subunit of both interleukin (IL)-12 and IL-23(1) . It has shown to be very effective in the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis with a good safety profile(2,) .In the last ten years, the appearance of antinuclear antibodies (ANA) and the induction of autoimmune diseases during treatment with tumour necrosis factor-alpha (TNFα) inhibitors has been described (3-4) . Read More

    Long-term treatment of chronic plaque psoriasis with biological drugs can control platelet activation: targeting the bridge between inflammation and atherothrombosis.
    Postepy Dermatol Alergol 2017 Apr 13;34(2):131-137. Epub 2017 Apr 13.
    Department of Dermatology, Medical University of Lodz, Lodz, Poland.
    Introduction: Platelet activation is elevated in moderate to severe psoriasis, and the reduction in platelet activation during short-term treatment has already been demonstrated. Soluble P-selectin is a well-established marker of platelet activation.

    Aim: To show whether the long-term treatment of psoriasis with biological drugs can reduce elevated platelet activation. Read More

    Topical 0.25% Desoximetasone Spray Efficacy for Moderate to Severe Plaque Psoriasis: A Randomized Clinical Trial.
    J Dermatolog Treat 2017 May 13:1-14. Epub 2017 May 13.
    a Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine , Winston-Salem , North Carolina.
    Background: Traditionally, ointments were the vehicle of choice for psoriasis. Poor adherence of traditional vehicles limits the use of topical corticosteroids. Alternative formulations have gained popularity due to their ease of application, improved adherence, and efficacy. Read More

    Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.
    Lancet 2017 May 11. Epub 2017 May 11.
    Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway. Electronic address:
    Background: TNF inhibitors have improved treatment of Crohn's disease, ulcerative colitis, spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and chronic plaque psoriasis, but are expensive therapies. The aim of NOR-SWITCH was to examine switching from originator infliximab to the less expensive biosimilar CT-P13 regarding efficacy, safety, and immunogenicity.

    Methods: The study is a randomised, non-inferiority, double-blind, phase 4 trial with 52 weeks of follow-up. Read More

    Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis. Data from the Psobiosimilars registry.
    Br J Dermatol 2017 May 12. Epub 2017 May 12.
    Department of Medicine, Section of Dermatology and Venereology, University of Verona, Italy.
    Infliximab is a chimeric human-murine monoclonal antibody that is very effective in chronic plaque psoriasis reaching a Psoriasis Area and Severity Index (PASI) 75 response in 80.4% of patients at week 10.(1) The more common adverse events include infusion reactions and upper respiratory tract infections. Read More

    Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis.
    Br J Dermatol 2017 May 12. Epub 2017 May 12.
    Dalhousie University, Halifax, NS, Canada.
    Clinical trials of biologic therapies in psoriasis usually evaluate fixed dosing regimens. It is well-known, however, that patients prescribed biologics may occasionally need to interrupt therapy for reasons such as surgery, changes in healthcare coverage, or pregnancy.(1) Consequently, dermatologists need to know whether interruption of biologic therapy may be associated with diminished response upon retreatment. Read More

    Serum YKL-40 as a potential biomarker of inflammation in psoriasis.
    J Dermatolog Treat 2017 May 12:1-21. Epub 2017 May 12.
    a Department of Dermatology and Venereology Medical University of Bialystok , 15-540 Bialystok , Zurawia 14 St , Poland.
    Objective: YKL-40 is an inflammatory glycoprotein associated with atherosclerosis, cardiovascular disease, diabetes or metabolic syndrome which are common comorbidities in psoriasis. The aim of the study was to assess serum YKL-40 level in psoriasis and elucidate possible associations with disease activity, inflammatory or metabolic parameters and treatment.

    Methods: A total of 37 individuals with active plaque-type psoriasis and 15 healthy controls were enrolled. Read More

    What Is Clearance Worth? Patients' Stated Risk Tolerance for Psoriasis Treatments.
    J Dermatolog Treat 2017 May 12:1-25. Epub 2017 May 12.
    c Eli Lilly and Company , Indianapolis , Indiana , USA.
    Purpose: The purpose of this study was to provide quantitative evidence of patients' tolerance for therapeutic risks associated with psoriasis treatments that could offer psoriasis improvements beyond the PASI 75 benchmark.

    Materials And Methods: We used a discrete-choice experiment in which respondents chose between competing psoriasis treatments characterized by benefits (ie, reduced plaque severity, reduced plaque area), risks (ie, 10-year risk of tuberculosis, 10-year risk of death from infection), and treatment regimen. We analyzed choice data using random-parameters logit models for psoriasis affecting the body, face, or hands. Read More

    Desoximetasone 0.25% spray, adrenal suppression and efficacy, in extensive plaque psoriasis.
    J Dermatolog Treat 2017 May 12:1-11. Epub 2017 May 12.
    a Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine , Winston-Salem , North Carolina.
    Background: In extensive psoriasis, topical corticosteroids are generally only used to supplement phototherapy and systemic therapy. Spray formulations are easier than other vehicle preparations to apply and may be an option for treating extensive psoriasis.

    Objective: To evaluate the potential for hypothalamic-pituitary-adrenal axis suppression and efficacy of topical desoximetasone 0. Read More

    Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and mean platelet volume in Japanese patients with psoriasis and psoriatic arthritis: Response to therapy with biologics.
    J Dermatol 2017 May 11. Epub 2017 May 11.
    Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
    Recent studies indicate the presence of systemic inflammation in psoriatic patients, and this inflammatory status is significantly associated with a range of comorbidities. The aim of this study was to evaluate the clinical significance of novel inflammatory biomarkers, neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and mean platelet volume (MPV) in Japanese patients with plaque-type psoriasis (PsV) and psoriatic arthritis (PsA). One hundred and eighty-six patients with PsV and 50 patients with PsA treated with biologics, including infliximab, adalimumab and ustekinumab, were retrospectively analyzed before and after treatment. Read More

    Efficacy and safety of secukinumab in Taiwanese patients with moderate to severe plaque psoriasis: Subanalysis from ERASURE phase III study.
    J Dermatol 2017 May 11. Epub 2017 May 11.
    Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
    The efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has been evaluated for moderate to severe plaque psoriasis in global trials which have included a low proportion of Asian subjects. We analyzed the efficacy and safety of secukinumab in Taiwanese patients in a phase III global clinical trial (ERASURE). Fifty-one Taiwanese patients were randomized into s. Read More

    Narrowband ultraviolet B light treatment changes plasma concentrations of MMP-3, MMP-9 and TIMP-3 in psoriatic patients.
    Ther Clin Risk Manag 2017 27;13:575-582. Epub 2017 Apr 27.
    Department of Esthetic Medicine.
    Background: Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) are thought to be associated with the pathogenesis and spread of psoriatic disease. This study was designed to investigate the plasma levels of MMP-3, MMP-9 and TIMP-3 in plaque psoriasis patients prior to and following a course of ultraviolet B narrowband treatment with respect to disease advancement.

    Methods: Plasma samples of 49 patients suffering from plaque psoriasis and 40 healthy volunteers were evaluated. Read More

    Biologics and Dermatology Life Quality Index (DLQI) in the Australasian Psoriasis Population.
    J Dermatolog Treat 2017 May 10:1-18. Epub 2017 May 10.
    a Skin and Cancer Foundation Inc , Carlton , Victoria , Australia.
    Background/objectives: Psoriasis is a chronic condition that may require long-term treatment for disease control. This analysis utilises data from the Australasian Psoriasis Registry with particular attention to the impact of biologic therapy on DLQI, and the differences between the biologics in terms of DLQI score change.

    Methods: A retrospective review of patients enrolled in the Australasian Psoriasis Registry from April 2008 to August 2016 was conducted. Read More

    Adverse events associated with discontinuation of the biologics/classic systemic treatments of moderate-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm.
    J Eur Acad Dermatol Venereol 2017 May 9. Epub 2017 May 9.
    Research Unit., Fundación Piel Sana Academia Española de Dermatología y Venereología, Madrid, Spain.
    Background: Little is known about the adverse events (AEs) that lead to suspension of systemic treatments of psoriasis in clinical practice.

    Objective: The study aimed to investigate to AEs associated with discontinuation of systemic therapy in patients with psoriasis in a clinical setting (Biobadaderm).

    Materials And Methods: Multicenter, prospective, cohort study of patients with moderate-to-severe plaque psoriasis receiving systemic therapies from January 2008 to November 2015, in 12 hospitals in Spain. Read More

    Coronary Plaque Characterization in Psoriasis Reveals High Risk Features Which Improve Following Treatment in a Prospective Observational Study.
    Circulation 2017 May 8. Epub 2017 May 8.
    National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), Bethesda, MD
    Background -Psoriasis, a chronic inflammatory disease associated with an accelerated risk of MI, provides an ideal human model to study inflammatory atherogenesis in vivo We hypothesized that the increased cardiovascular risk observed in psoriasis would be partially attributable to an elevated subclinical coronary artery disease (CAD) burden composed of non-calcified plaques with high-risk features. However, inadequate efforts have been made to directly measure CAD in this vulnerable population. As such, we sought to compare total (TB) and non-calcified (NCB) coronary plaque burden, and high-risk plaque (HRP) prevalence, between psoriasis patients (n=105), hyperlipidemic patients eligible for statin therapy under NCEP-ATP III guidelines (n=100) who were ~10 years older, and non-psoriasis healthy volunteers (HV) (n=25). Read More

    Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial.
    Lancet 2017 May 4. Epub 2017 May 4.
    AbbVie, North Chicago, IL, USA.
    Background: Adalimumab is indicated for the treatment of moderate to severe psoriasis in adults. We assessed the efficacy and safety of adalimumab in children and adolescents with severe plaque psoriasis.

    Methods: This randomised, double-blind, multiperiod, phase 3 trial was done at 38 clinics in 13 countries. Read More

    Polymorphisms associated with etanercept response in moderate-to-severe plaque psoriasis.
    Pharmacogenomics 2017 May 4;18(7):631-638. Epub 2017 May 4.
    Clinical Pharmacology Department, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IIS-IP), Madrid, Spain.
    Aim: Few studies have evaluated the influence of pharmacogenetics in psoriatic patients treated with etanercept.

    Materials & Methods: We evaluated the association between 124 polymorphisms with the response to etanercept in patients with moderate-to-severe plaque psoriasis at 3 months (n = 78) and 6 months of treatment (n = 68).

    Results: The results of the multivariate analysis showed an association between polymorphisms rs13437088 (HLA-B/MICA), rs96844 (MAP3K1), rs2431697 (PTTG1), rs9304742 (ZNF816A) and the response to etanercept at 3 months. Read More

    The Challenge of Managing Psoriasis: Unmet Medical Needs and Stakeholder Perspectives.
    Am Health Drug Benefits 2016 Dec;9(9):504-513
    Professor of Dermatology, Department of Dermatology, New York Medical College, Valhalla, NY.
    Background: Psoriasis is a debilitating chronic inflammatory autoimmune disease affecting approximately 7.4 million adults in the United States. Plaque psoriasis is the most common form, affecting 80% to 90% of patients. Read More

    Emerging targeted therapies for plaque psoriasis - impact of ixekizumab.
    Clin Cosmet Investig Dermatol 2017 21;10:133-139. Epub 2017 Apr 21.
    University of California - Los Angeles, David Geffen School of Medicine, Los Angeles, CA.
    Background: Recent studies into the pathogenesis of psoriasis have identified the importance of interleukin 17 (IL-17) in disease activity and have thus provided a new target for biologic therapy. Ixekizumab, the most recent US Food and Drug Administration (FDA)-approved anti-IL-17 biologic agent, appears to be a promising medication for patients suffering from moderate-to-severe plaque psoriasis.

    Methods: We reviewed the results of phase III trials for ixekizumab in order to assess the efficacy, safety, and impact on quality of life of this agent in the treatment of plaque psoriasis. Read More

    Polyphenotypic Psoriasis: A Report from the GRAPPA 2016 Annual Meeting.
    J Rheumatol 2017 May;44(5):695-696
    From the Department of Dermatology, Warren Alpert Medical School, Brown University, Providence, Rhode Island; Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
    Recent groundbreaking therapies for psoriasis target specific pathways that drive this systemic inflammatory disease. However, patients with nonplaque psoriasis phenotypes often do not qualify for these therapies and are currently undertreated because of the criteria used during the development of novel agents. We propose use of the phrase "polyphenotypic psoriasis" to describe both plaque and nonplaque subtypes, as well as single and multiple phenotype involvement in individual patients. Read More

    Basic and Translational Science: A Report from the GRAPPA 2016 Annual Meeting.
    J Rheumatol 2017 May;44(5):679-683
    From Clinical Investigation, The Rockefeller University, New York; Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, New York, USA; Guy's and St. Thomas' UK National Health Service (NHS) Foundation Trust; King's College London, London, UK.
    Rapid advances in effective treatments for psoriasis and psoriatic arthritis (PsA) have emerged from improved understanding of cell subsets and critical mediators that promote tissue inflammation and destruction. More specifically, increased knowledge of innate immunity and the important involvement of cytokines in the interleukin (IL)-23-IL-17 axis as key mediators of psoriatic plaque and joint inflammation in both psoriasis and PsA have led to new theories of immunopathogenesis. Herein we summarize recent discussions on IL-17-related pathways and their relationship to psoriasis and PsA. Read More

    Reply to 'Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials'.
    Br J Dermatol 2017 Apr 29. Epub 2017 Apr 29.
    Kaiser Permanente Los Angeles Medical Center, Department of Dermatology, Los Angeles, CA, USA.
    We read with interest the recent article by Rungapiromnan et al. that utilized a meta-analysis to compile data from 38 randomized controlled trials (RCTs) to determine if there is an association between biologic therapies and major adverse cardiovascular events (MACEs) in patients with plaque psoriasis. In the current study, only 10 MACEs were reported over nine of the RCTs examined. Read More

    The cost-effectiveness of blue-light therapy in the treatment of mild-to-moderate psoriasis.
    J Comp Eff Res 2017 Apr 28. Epub 2017 Apr 28.
    Institute for Medical Technology Assessment, Institute of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.
    Aim: To investigate the cost-effectiveness of blue-light therapy versus a two-compound formulation (TCF) (Dovobet(®) gel [calcipotriol and betamethasone]) in mild-to-moderate psoriasis.

    Methods: A Markov model was applied to describe the course of disease among Dutch patients with a Psoriasis Area and Severity Index (PASI) score ≤ 10 over a 52-week time horizon. Patients received either 12-week blue-light therapy or two 4-week treatments with TCF. Read More

    Hypodermal Adipose Tissue Sonoelastography for Monitoring Treatment Response in Patients with Plaque Psoriasis.
    Photomed Laser Surg 2017 Apr 24. Epub 2017 Apr 24.
    2 Department of Diagnostic and Molecular Imaging, Interventional Radiology and Radiotherapy, University of Rome "Tor Vergata ," Rome, Italy .
    Background: Psoriasis (PsO) is a multifactorial chronic and relapsing skin disease that affects about 125 million people in the world. Several studies have demonstrated the link between adipose tissue, inflammation, and PsO. The purpose of our study is to evaluate hypodermal adipose tissue inflammation underneath PsO plaques quantifying tissue elasticity with sonoelastography before and after treatment. Read More

    Alitretinoin therapy for palmoplantar pustulosis.
    Br J Dermatol 2017 Apr 26. Epub 2017 Apr 26.
    Dermatology Unit, Galliera Hospital, Genoa, Italy.
    We read with interest the RCT by Reich et al., and we found that the conclusion given: "this study provided no evidence to support further exploration of alitretinoin in the treatment of severe palmoplantar pustulosis (PPP)" should be carefully interpreted.(1) The authors found no significant difference in the percentage change in PPPASI between the alitretinoin (45. Read More

    The safety of ustekinumab for the treatment of psoriatic arthritis.
    Expert Opin Drug Saf 2017 May 9:1-9. Epub 2017 May 9.
    a Department of Dermatology , Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona , Barcelona , Spain.
    Introduction: The cytokines interleukin (IL)-12 and IL-23 have been involved in the pathogenesis of psoriasis and psoriatic arthritis. Ustekinumab is a fully human monoclonal antibody targeting the p40 subunit shared by IL-12 and IL-23. Ustekinumab prevents the interaction of IL-12 and IL-23 binding to their receptors, blocking the T1 and T17 inflammatory pathways. Read More

    The GENDER ATTENTION Observational Study: Gender and Hormonal Status Differences in the Incidence of Adverse Events During Cyclosporine Treatment in Psoriatic Patients.
    Adv Ther 2017 Apr 21. Epub 2017 Apr 21.
    UCB Pharma Italia, Milan, Italy.
    Introduction: Female sex has been shown to be a risk factor for the development of adverse drug reactions; however, this has not been studied for cyclosporine (CsA). The aim of this study was to investigate, in Italian dermatological practice, the influence of gender and menopause and related hormones on the incidence of adverse events (AEs) during CsA treatment in psoriatic patients.

    Methods: Multicenter, prospective, observational study conducted from May 2011 to June 2013. Read More

    Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
    N Engl J Med 2017 04;376(16):1551-1560
    From K. Papp Clinical Research and Probity Medical Research, Waterloo, ON (K.A.P.), School of Medicine, Queen's University, Kingston, ON (M.G.), and Centre for Dermatology and Probity Medical Research, Peterborough, ON (M.G.) - all in Canada; Oregon Medical Research Center, Portland (A.B.); Altman Dermatology Associates, Arlington Heights, IL (M.B.); Rockefeller University, New York (J.K.); Hôpital de l'Archet, University of Nice-Sophia Antipolis, Nice, France (J.-P.L.); Baylor Research Institute, Dallas (A.M.); Charité Universitätsmedizin Berlin, Berlin (S.P.), Boehringer Ingelheim Pharma, Biberach (B.R.B.), and Boehringer Ingelheim Pharma, Ingelheim, (S.J.P.) - all in Germany; University of Texas Health Science Center, Houston (S.T.); University of California, Los Angeles, School of Medicine, Los Angeles (H.S.); and Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (S.V., C.P., N.B., M.F., P.S.).
    Background: Interleukin-23 is thought to be critical to the pathogenesis of psoriasis. We compared risankizumab (BI 655066), a humanized IgG1 monoclonal antibody that inhibits interleukin-23 by specifically targeting the p19 subunit and thus prevents interleukin-23 signaling, and ustekinumab, an interleukin-12 and interleukin-23 inhibitor, in patients with moderate-to-severe plaque psoriasis.

    Methods: We randomly assigned a total of 166 patients to receive subcutaneous injections of risankizumab (a single 18-mg dose at week 0 or 90-mg or 180-mg doses at weeks 0, 4, and 16) or ustekinumab (45 or 90 mg, according to body weight, at weeks 0, 4, and 16). Read More

    Expression of low-density lipoprotein related receptors 5 and 6 (LRP5/6) in psoriasis skin.
    Exp Dermatol 2017 Apr 18. Epub 2017 Apr 18.
    Division of Dermatology and Venereology, Region Jönköping County, Jönköping, Sweden.
    Low-density lipoprotein-related receptors 5 and 6 (LRP5/6) are transmembrane receptors with key functions in canonical Wnt signaling. Wnt ligands are thought to play an important role in innate immunity and psoriasis and recent studies assigned LRP5/6 anti-inflammatory properties. The objective of this study was to investigate the expression of LRP5 and LRP6 in lesional and non-lesional skin in peripheral blood and in mononuclear cells of patients with chronic plaque type psoriasis compared with control individuals. Read More

    Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).
    J Am Acad Dermatol 2017 Apr 14. Epub 2017 Apr 14.
    Modern Research Associates, Dallas, Texas.
    Background: Randomized, controlled trials demonstrated efficacy and safety of apremilast for moderate-to-severe plaque psoriasis and psoriatic arthritis.

    Objective: Assess long-term safety of oral apremilast in psoriasis patients.

    Methods: Safety findings are reported for 0 to ≥156 weeks from the Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) 1 and 2. Read More

    Comparison of Occlusive and Open Application in a Psoriasis Plaque Test Design, Exemplarily Using Investigations of Mapracorat 0.1% Ointment versus Vehicle and Reference Drugs.
    Skin Pharmacol Physiol 2017 14;30(2):102-114. Epub 2017 Apr 14.
    bioskin GmbH, Hamburg, Germany.
    Background/aims: Psoriasis plaque tests (PPTs) are important tools in the early phases of antipsoriatic drug development. Two distinct PPT design variants (open vs. occluded drug application) are commonly used, but no previous work has aimed to directly compare and contrast their performance. Read More

    Secukinumab - First in Class Interleukin-17A Inhibitor for the Treatment of Psoriasis.
    Indian J Dermatol 2017 Mar-Apr;62(2):195-199
    Department of Dermatology, D Y Patil University School of Medicine, Navi Mumbai, Maharashtra, India.
    Psoriasis is a complex inflammatory disease that occurs in genetically susceptible individuals and presents with the development of erythematous scaly plaques on the skin. Interleukins (ILs) in the Th17 pathway play a pivotal role in the pathogenesis of psoriasis and have thus become targets for recent biologic drug development. Secukinumab is a human monoclonal IgG1k antibody that has been developed to target and block the actions of IL-17A. Read More

    Efficacy and safety of total glucosides of paeony combined with acitretin in the treatment of moderate-to-severe plaque psoriasis: a double-blind, randomised, placebo-controlled trial.
    Eur J Dermatol 2017 Apr;27(2):150-154
    Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
    Although acitretin has been widely used for the treatment of psoriasis, additional safer and more effective approaches, including traditional Chinese medicine, are needed. To investigate the efficacy and safety of total glucosides of paeony (TGP) combined with acitretin in the treatment of moderate-to-severe plaque psoriasis. A randomised, double-blind, placebo-controlled, multi-centre clinical study was conducted. Read More

    Misdiagnosed crusted scabies in an AIDS patient leads to hyperinfestation.
    Cutis 2017 Mar;99(3):202-204
    University of Texas Medical Branch, Galveston, USA.
    Crusted scabies is a severe, highly contagious form of classic scabies caused by the mite Sarcoptes scabiei var hominis. Crusted scabies is more common in immunosuppressed populations and overcrowded environments. In this condition, the host's immune system is overwhelmed and unable to defend against the mites on the skin, resulting in hyperinfestation of the host. Read More

    Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials.
    Adv Ther 2017 Apr 10. Epub 2017 Apr 10.
    Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
    Introduction: There is little evidence available on the efficacy and safety of biologic therapies for the treatment of psoriasis in Hispanic patients. Secukinumab is demonstrated to be highly effective for clearing psoriasis. The aim of this study was to compare the efficacy and safety of secukinumab in Hispanic and non-Hispanic patients. Read More

    Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis.
    J Am Acad Dermatol 2017 Apr 7. Epub 2017 Apr 7.
    Pfizer Inc, Collegeville, Pennsylvania. Electronic address:
    Background: Tofacitinib is an oral Janus kinase inhibitor. Efficacy and safety of tofacitinib in patients with moderate-to-severe plaque psoriasis have been demonstrated.

    Objective: We sought to assess the efficacy of tofacitinib for the treatment of nail psoriasis over a period of 52 weeks. Read More

    Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
    J Dermatol 2017 Apr 9. Epub 2017 Apr 9.
    Kojinkai Sapporo Skin Clinic, Sapporo, Japan.
    Apremilast, an oral, small-molecule phosphodiesterase 4 inhibitor, works intracellularly within immune cells to regulate inflammatory mediators. This phase 2b randomized, placebo-controlled study evaluated efficacy and safety of apremilast among Japanese patients with moderate to severe plaque psoriasis. In total, 254 patients were randomized to placebo, apremilast 20 mg b. Read More

    The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies.
    J Allergy Clin Immunol 2017 Apr;139(4S):S65-S76
    Department of Pediatrics, National Jewish Health, Denver, Colo. Electronic address:
    Atopic dermatitis (AD), the most common chronic inflammatory skin disease, is driven by both terminal keratinocyte differentiation defects and strong type 2 immune responses. In contrast to chronic plaque-type psoriasis, AD is now understood to be a much more heterogeneous disease, with additional activation of TH22, TH17/IL-23, and TH1 cytokine pathways depending on the subtype of the disease. In this review we discuss our current understanding of the AD immune map in both patients with early-onset and those with chronic disease. Read More

    Nail psoriasis - what a rheumatologist should know about.
    Reumatologia 2017 22;55(1):44-47. Epub 2017 Mar 22.
    Chair and Department of Hygiene, Medical University of Lublin, Poland.
    Psoriasis is a chronic recurrent inflammatory skin disease with prevalence of 1-3%. Nail psoriasis affects 10-90% of patients with plaque psoriasis. The aim of the article is to review the literature for the correlation between nail psoriasis and psoriatic arthritis (PsA) to provide rheumatologists a short review on features of nail psoriasis, methods of their assessment and possible clinical repercussions. Read More

    Metabolic Syndrome in Psoriasis among Urban South Indians: A Case Control Study Using SAM-NCEP Criteria.
    J Clin Diagn Res 2017 Feb 1;11(2):WC01-WC04. Epub 2017 Feb 1.
    Junior Resident, Department of Dermatology, K.S Hegde Medical Academy , Mangalore, Karnataka, India .
    Introduction: Psoriasis is a chronic inflammatory disease of the skin associated with increased cardiovascular morbidity. Metabolic syndrome is a significant forecaster of cardiovascular events.

    Aim: To assess the association of metabolic syndrome and its components in patients with psoriasis and to compare it with the age and sex matched control group. Read More

    The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature.
    Mol Diagn Ther 2017 Apr 3. Epub 2017 Apr 3.
    Department of Dermatology, University of Rome Tor Vergata, Viale Oxford, 81-00133, Rome, Italy.
    Psoriasis is a chronic inflammatory disease triggered by both genetic and environmental factors. Systemic and biologic therapies used to treat moderate-to-severe psoriasis show significant variability in efficacy, are associated with various degrees of toxicity, and, for biologic therapies, are expensive. There is a great need for non-invasive biomarkers to predict treatment outcomes of these therapies and to individualize care for patients with psoriasis. Read More

    The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis.
    J Eur Acad Dermatol Venereol 2017 Apr 1. Epub 2017 Apr 1.
    St. Louis University School of Medicine, St. Louis, MO, USA.
    Background: There is concern that increased bodyweight may impact efficacy of some therapies used to treat psoriasis.

    Objective: To evaluate the effect of bodyweight on response to ixekizumab treatment in patients with moderate-to-severe psoriasis.

    Methods: Patients were characterized under three bodyweight categories (<80 kg, 80 to <100 kg, ≥100 kg) in this preplanned subgroup analysis from an integrated database of three multicenter, randomised, double-blind, controlled Phase 3 clinical studies (UNCOVER-1, UNCOVER-2 and UNCOVER-3). Read More

    Effectiveness of adalimumab in the treatment of scalp and nail affection in patients with moderate to severe plaque psoriasis in routine clinical practice.
    Acta Dermatovenerol Alp Pannonica Adriat 2017 Mar;26(1):11-14
    Global Medical Affairs Immunology, AbbVie, Ljubljana, Slovenia.
    Introduction: Data on the effectiveness of biologics in the treatment of nail and scalp psoriasis (PSO) in a routine clinical setting are scarce. The aim of this study was therefore to evaluate the effectiveness of adalimumab in the treatment of nail and scalp psoriatic lesions in routine dermatologic practice.

    Methods: Five hundred one patients were analyzed in this observational study; 157 patients had nail involvement (nail PSO set; NPS) and 404 had scalp involvement (scalp PSO set; SPS). Read More

    1 OF 68